Diagnostics for glucose-6-phosphate dehydrogenase (G6PD) deficiency
Advancing new diagnostics to detect a common hereditary enzyme deficiency that complicates treatment for malaria
G6PD deficiency and P. vivax malaria
Malaria is a serious and even deadly disease spread by mosquitoes. As many as 2.85 billion people are estimated to be at risk of Plasmodium vivax malaria, a form common in Asia, Latin America, and East Africa. P. vivax is the most difficult form of malaria to eliminate because it causes recurring illness, which perpetuates the cycle of infection. All malaria parasites in the body must be killed to stop this cycle. This is known as radical cure.
Currently, radical cure for P. vivax malaria can only be achieved with primaquine, an 8-aminoquinoline-based drug. But this class of drug can cause potentially lethal side effects in people with a common deficiency of an enzyme known as glucose-6-phosphate dehydrogenase (G6PD). Therefore, it is critical for all patients to be tested for G6PD deficiency before they are treated with primaquine.
Providing safe treatment, accelerating elimination
Existing diagnostics for G6PD deficiency are not sufficient to support scaling up of treatment of P. vivax. A point-of-care diagnostic tool for G6PD deficiency is needed to support appropriate treatment of patients with P. vivax malaria and accelerate elimination of the disease.
PATH and our partners are advancing new diagnostic tests for G6PD deficiency that may help guide appropriate clinical care of patients and support P. vivax elimination efforts. PATH has taken a portfolio approach, working with multiple diagnostic test developers to develop and evaluate G6PD diagnostic tests.
Learn more in our G6PD fact sheet.
New publication: The G6PD flow-cytometric assay is a reliable tool for diagnosis of G6PD deficiency in women and anaemic subjects. Scientific Reports, 2017.
Posters and presentations
- Quantitative Point-of-Care G6PD Tests for Radical Cure of Plasmodium vivax Malaria
- Using Modeled Plasmodium vivax Prevalence Data to Estimate the Market Size for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Tests In Order To Support Decision-Making on Service Delivery Models
- Recombinant human G6PD for quality control and quality assurance: resource for robust G6PD testing in Plasmodium vivax radical cure
- Specimen repository for evaluating new point-of-care tests for G6PD deficiency
- Implementing interactive geospatial tools in R for cost analysis of diagnostic platforms for G6PD deficiency
- Evaluation of diagnostic platforms for G6PD deficiency
- Maintaining specimen integrity for screening G6PD activity
- Development of new modeling tools to improve determination of G6PD status
- Specimen repository for evaluating new point-of-care tests for G6PD deficiency: a resource for accelerating diagnostic product development
News and media
- Press release – PATH announces agreement with BD to advance new diagnostic technologies to support malaria elimination
- Article – Building capacity for G6PD testing to support P. vivax malaria elimination
- Announcement – PATH and GSK partner to develop G6PD diagnostic
- Press release – Department for International Development (UK) award
Gonzalo Domingo, Malaria Portfolio Leader
Nicole Advani, Program Coordinator
This project is supported by grants from the Bill & Melinda Gates Foundation and the Department for International Development.